Please assess the completion status of the following clinical trial:

Trial Title: SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients should be voluntarily sign the written informed consent.~2. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic squamous NSCLC. Or recurrent squamous NSCLC according UICC/AJCC 8th edition.~3. At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously irradiated could be considered as a target lesion only in the condition that progression occurred at the time of 3 months after the end of radiotherapy.~4. Previously treated with one platinum based regimen (including platinum and endostar regimen) and progression occur during or after treatment or unbearable treatment related adverse events.~5. Progression after EGFR-TKIs in patients with driver gene mutation.~6. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.~Exclusion Criteria:~1. Patient who is allergic to recombinant humanized PD-1 monoclonal antibody or the components of the drug.~2. Patient who is allergic to taxane.~3. Previously treated with any of the antibodies targeted on PD-1, PD-L1, PD-2, CD137, CTLA-4, T cell, co-stimulation or drugs targeted on the checkpoint signal pathway.~4. Previously treated with docetaxel.~5. The histopathological subtype is not squamous cell non-small cell lung cancer, or squamous cell \< 90% in a mixed carcinoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SCT-I10A plus Docetaxel (Type: EXPERIMENTAL): SCT-I10A 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W. Maximum of 6 cycles
- Placebo puls docetaxel (Type: ACTIVE_COMPARATOR): Placebo 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W Maximum of 6 cycles
- Maintenance therapy of SCT-I10A (Type: EXPERIMENTAL): Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: SCT-I10A 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
- Maintenance therapy of Placebo (Type: PLACEBO_COMPARATOR): Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: Placebo 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).